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To the Editors:
Botulinum toxin type A is a biochemical neuromodulator 
known to block cholinergic transmission at the neuromuscular 
junction. Over the last two decades, the localised efficacy of 
botulinum toxin A, and its well-tolerated safety profile, have 
resulted in a significant growth of its on- and off-label use across 
multiple therapeutic and aesthetic indications [1]. It has also been 
shown to be effective in the gastrointestinal tract [2–4]. Until 
now, injections of botulinum toxin have been used in the treat-
ment of, inter alia, chronic idiopathic constipation in children, 
anal fissure both in children and adults, as well as obstructive 
symptoms in children with Hirschsprung Disease [5–7]. Botu-
linum toxin injections are also effective in short-term anismus, 
defined as a functional disorder of the defecation process that 
entails relaxation failure or even paradoxical contraction of the 
puborectalis muscle and contraction of the external anal sphinc-
ter during defecation [8]. Zhang et al. evaluated the efficacy of 
botulinum toxin type A injection to the puborectalis and external 
sphincter muscle in the treatment of 31 patients in whom previ-
ous biofeedback therapy had proved unsatisfactory [9]. Chronic 
constipation scoring system and anorectal manometry showed 
that the injection of botulinum toxin, combined with pelvic floor 
biofeedback training, was effective in 24 of the 31 patients [9].
Case report
In November 2018, during post-stroke rehabilitation, 
a 64-year-old female patient was transferred to the Internal 
Medicine Department due to severe abdominal distension with 
symptoms of large bowel obstruction. The previous month, 
she had suffered a stroke to the left hemisphere, was treated 
with thrombolysis and thrombectomy, but was left hemiplegic. 
A differential diagnosis was performed to exclude malignant 
obstructing diseases or benign conditions such as sigmoid 
volvulus, diverticulitis or colonic ischaemia. Abdominal and 
pelvic CT with contrast revealed the persistence of a large faecal 
impaction located in the sigmoid colon and a massive dilatation 
from the caecum to the rectum, with transverse colon of up to 
approximately 75 mm [normal value: < 60 mm] [10], sigmoid 
colon of up to 100 mm [normal value: < 65 mm] [10] and rectal 
ampulla of up to 58 mm [normal value: < 40 mm] [10] (Fig. 
1). The patient was diagnosed with megacolon in the course 
of anal spasticity secondary to the stroke. Although the patient 
had never previously suffered from chronic constipation, at the 
time of admission she had a complex medical history including 
hypertension, atrial fibrillation, dehydration and hypopotas-
semia. Laboratory tests, including blood morphology, CRP and 
Clostitdium diff., were negative. Physical examination found 
no signs of fever or tachycardia. Multiple laxatives, enemas 
and prokinetic agents (e.g. metoclopramide) were introduced. 
However, no clinical improvement was noted. Pulsed irrigation 
and abdominal massage yielded only a slight, transient effect. 
Therefore, a colonic-rectal tube was inserted. The expulsion of 
a large volume of gas led to significant, but only transient, relief of 
the abdominal distension and reduction of abdominal symptoms. 
After six days of conservative treatment, the abdomen 
remained visibly distended, and the patient’s general condition 
had deteriorated. Moreover, her CRP level had increased to 
25.6 mg/l [normal value: < 5.0], and white blood cell count 
elevated to 16x 109/L. Surgical consultations confirmed 
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a redundant megacolon with a high risk of bowel wall ischaemia 
or/and perforation. Therefore, an elective colectomy was sched-
uled. However, due to the need to treat coexisting conditions, 
the surgery was postponed. A radiographic examination at the 
beginning of January 2019 revealed a colonic dilatation of up 
to 130 mm and rectal dilatation of up to 51 mm (Suppl. Fig. 2). 
Since several per-rectum examinations revealed anal spasm, 
the patient was proposed incobotulinumtoxinA injection in 
the external anal sphincter as a bridge therapy. 
Intervention
At the end of January 2019, the patient in the lithotomy 
position was injected with 70 U of incobotulinumtoxinA dilut-
ed in 2 ml of saline into the external anal sphincter. Injections 
were administered unilaterally, either via the intra-anal or 
perianal region (35 U on each side). The patient was discharged 
four days after the initial admission. On discharge, the abdo-
men remained only slightly distended. The patient was passing 
4–8 loose stools and not vomiting. An X-ray examination given 
four days after the injections revealed colonic dilatation of up 
to 120–130 mm and rectal dilatation of up to 34 mm (Suppl. 
Fig. 3). The patient was discharged from the ward. Two weeks 
following the procedure, a per-rectum examination showed 
decreased sphincter spasticity, as well as a significant, notice-
able reduction of abdominal symptoms. Although control of 
the anal sphincter was not fully regained, reduced constipation 
led to a remarkable improvement in the quality of life. 
The procedure was repeated after three months, in April 2019. 
Due to the improvement of the patient’s condition, the dose of 
incobotulinumtoxinA was lowered to 50 U (25 U on each side) 
to prevent excessive external anal sphincter relaxation. The same 
technique of injection was applied. Two weeks after this administra-
tion, the patient had partially regained control of the anal sphincter. 
It is important to note that the two-month rehabilitation 
(June–July 2019) did not influence the overall neurological 
condition. Kinesitherapy did not significantly improve the 
patient’s motor function, and continuous logotherapy led to 
only partial recovery from aphasia. After rehabilitation, hemi-
plegia turned into hemiparesis, and the patient was discharged 
in a wheelchair.
After another six months, in October 2019, the therapeutic 
effect of injections was sustained. The patient regained full 
control of the external anal sphincter and controlled defecation 
herself. A lower gastrointestinal series examination revealed 
the width of the rectal ampulla at 36 mm (Suppl. Fig. 4).
In this case report, we demonstrate the potential of botu-
linum toxin in the treatment of external anal sphincter spasm. 
An initial ‘rescue’ local injection of BoNT-A not only allowed 
surgical decompression of the GI tract to be avoided, but over 
the longer term also led to the regaining of full control of 
defecation in a post-stroke patient.
In conclusion, injections of BoNT-A may be a useful 
alternative treatment modality for post-stroke constipation, 
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dilatation of rectal ampulla
